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1. Introduction 
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by cardiac chamber 
enlargement and impaired systolic (and almost always diastolic) function. It is usually 
associated with heart failure, arrhythmias and/or conduction system disease and 
thromboembolic disease but may also be asymptomatic. DCM is diagnosed in the presence 
of left ventricular enlargement and systolic dysfunction (left ventricular ejection fraction less 
than 50% or fractional shortening of less than 25-30%). It is considered one of the most 
common causes of heart failure, resulting in considerable morbidity and mortality. Patients 
with DCM suffer from heart failure, arrhythmia and are at risk of premature death. The 
prevalence of dilated cardiomyopathy is one case out of 2500 patients with an incidence of 
7/100 000/year and it is 3 times more frequent in blacks and males than whites and females 
(Bender et al., 2011, Hershberger et al., 2007, Taylor et al., 2006). 
DCM may appear sporadic in a single member of family and is called then idiopathic DCM 
(IDC). Dilated cardiomyopathy may be also inherited and is termed familial DCM (FDC), 
contributing for 20-48 % of DCM. According to Mestroni et al. (1999), the diagnosis of FDC 
is made in the presence of two or more affected individuals in a single family or in the 
presence of a first-degree relative of a dilated cardiomyopathy patient with well 
documented unexplained sudden death at < 35 years of age. The principle causes of FDC are 
genetic mutations affecting cardiac myocytes (Taylor et al., 2006). Knowledge about genes 
involved in development of dilated cardiomyopathy can be used to create genetic tests for 
assessing the risk of DCM. 
As DCM is a multigenic disorder, there are many genes contributing to development of this 
disease. More than 30 genes, coding a variety of proteins such as nuclear envelope proteins, 
cardiac sarcomere units, ion channels, transcription factors, or dystrophin-associated 
cytoskeletal complex, were identified as causes of dilated cardiomyopathy (Hershberger et 
al., 2009a). Some of these genes (discussed in this chapter) are presented in Table 1. For 
additional information see Hershberger et al. (2010) and UpToDate® website. 
2.Major genetic causes of DCM 
2.1 Lamins A/C (LMNA) 
Nuclear lamins (see Figure 1) are intermediate filament-type proteins that are major 
building blocks of the nuclear lamina – a meshwork underlying the inner nuclear 
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membrane. They can also be localized in the nuclear interior. Nuclei assembled in vitro in 
the absence of lamins are fragile, indicating the role of lamins in stabilizing the cell nucleus. 
Lamins also take part in DNA replication, chromatin organization, spatial arrangement of 
nuclear pore complexes, nuclear growth and anchorage of nuclear envelope proteins 
(Stuurman et al., 1998). Patients carrying mutations in LMNA gene are known to be at risk 
of conduction disorders and arrhythmic events in addition to ventricular dilatation and 
heart failure (Haugaa et al., 2009). 
 
Gene Encoded protein Function 
Major genetic factors 
LMNA lamins A/C building blocks of nuclear lamina 
TNNT2 cardiac troponin T (cTnT) regulation of muscle contraction 
ǃ-MYH7 ǃ-myosin heavy chain conversion of chemical energy into mechanical 
force 
Other genetic factors 
SCN5A 
alpha subunit of type V 
voltage-gated sodium 
channel 
control of the flow of sodium ions into cardiac 
muscle cells 
TCAP titin-cap (telethonin) regulation of sarcomere assembly 
HBEGF 
heparin-binding epidermal 
growth factor 
regulation of cell growth and differentiation 
SRA1 
steroid receptor RNA 
activator 1 
stimulation of proliferation and apoptosis 
IK cytokine 
down-regulation of expression of HLA class II 
antigens 
TPM1 ǂ-tropomyosin regulation of actin-myosin interaction 
PSEN 1/2 presenilin 1 / 2 multi-pass transmembrane proteins 
Dnm1l dynamin-1-like establishing mitochondrial morphology 
LDB3 LIM domain binding 3 
interaction with ǂ-actinin-2 and protein kinase 
C 
Table 1. Genes associated with dilated cardiomyopathy 
Many studies suggest that defects in LMNA gene, encoding lamins A/C, are one of the most 
significant genetic causes of dilated cardiomyopathy. According to Colombo et al. (2008), the 
LMNA gene is involved in up to 30-50% of patients with cardiac conduction disorders and 
DCM. Arbustini et al. (2002) were one of the first to reveal the role of LMNA mutations in 
developing dilated cardiomyopathy. The researchers investigated the prevalence of LMNA 
gene defects in familial and idiopathic DCM associated with atrioventricular block or 
increased serum creatine-phosphokinase (sCPK). 73 cases of DCM (15 with atrioventricular 
block) were analysed, revealing five LMNA mutations (K97E, E111X, R190W, E317K and 4 
base pair insertion at 1713 cDNA) in five cases of familial autosomal dominant DCM with 
atrioventricular block (33%). The role of LMNA mutations was further confirmed by Hermida-
Prieto et al. (2004) in the study on 67 consecutive patients with DCM (18 with FDC, 17 with 
possible FDC and 32 with idiopathic DCM). The researchers observed two disease-causing 
mutations in LMNA gene, a novel R349L substitution and R190W (the same as in Arbustini et 
al. study). Both mutations were associated with severe forms of familial DCM. Another 
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discovery concerning lamins was brought by Kärkkäinen et al. (2006). The study was carried 
out on 66 DCM patients, who received heart transplant. DNA sequencing revealed 6 
mutations in LMNA gene (A132P, S143P, R190W, T1085 deletion, G1493 deletion, and R541S) 
which explained DCM in 9% patients. Moreover, one of these mutations (S143P) explained 7 % 
of all cases in an unselected DCM population. 
 
 
Fig. 1. Structure of human lamin. 
In order to investigate mechanism responsible for electrophysiologic and myocardial 
phenotypes caused by dominant human LMNA mutations, an experiment was carried out 
on heterozygous Lmna +/- mice (Wolf et al., 2008). Cardiac function and electrophysiology 
were examined in heterozygous mice which underwent a targeted deletion of LMNA gene 
resulting in reduced level of lamin A/C protein in hearts. The researchers found out that 
despite normal structure and function in young Lmna +/- mice, older mice had altered 
atrioventricular nodal architecture, functional electrophysiological deficits and arrhythmias. 
Moreover, aged Lmna +/- mice, similar to humans with LMNA mutations, developed DCM, 
sometimes without overt conductions system disease. 50-week old Lmna +/- mice had 
enlarged ventricular chambers in systole (p=0.01) and diastole (p=0.002) corresponding to 
significantly decreased fractional shortening (p=0.02). Cardiac sections of these mice also 
showed more fibrosis than wildtype mice. Cell and sarcomere shortening were decreased in 
Lmna +/- myocytes compared to wildtype (p<0.001) with ventricular dilatation and 
depressed cardiac contractility consistent with DCM in aged Lmna +/- mice. These findings 
confirmed lamin A/C haploinsufficency as a possible mechanism leading to DCM.  
Parks et al. (2008) were one of the first to carry out a research concerning lamins A/C 
mutation on a large group of patients. DNA from 324 patients with DCM (187 with FDC) 
was sequenced for nucleotide alterations in LMNA gene. 18 protein-altering variants (14 
novel) were identified in 5.9% cases (7.5% of FDC and 3.6% of IDC). 11 alterations were 
missense mutations (which changed conserved amino acid), three were nonsense, another 
three were insertion/deletion and one was a splice site alteration. Conduction system 
disease and DCM were common among the carriers of these LMNA variants. These findings 
were further investigated by Cowan et al. (2010), who expressed in COS7 cells GFP-
prelamin A constructs including 13 LMNA variants identified by Parks et al. (see Table 2). 
Confocal immunofluorescence microscopy was then used to characterize GFP-lamin A 
localization and nuclear morphology. Abnormal phenotypes were observed for 10 out of 13 
analyzed variants, providing evidence which supported pathogenicity of these variants. 
Recently, Botto et al. (2010) described additional novel LMNA mutation in FDC. Sequencing 
of the patient’s LMNA coding exons revealed heterozygous missense mutation cytosine to 
thymine at nucleotide 565 in exon 3 which caused a substitution of arginine to hydrophobic 
tryptophan (R189W mutation) in a conserved residue located in the coil 1b of the alpha-
helical rod domain. This mutation was located near the most prevalent lamin A/C mutation 
R190W, suggesting a “hot-spot” region at exon 3 and was not identified in a group of 50 
healthy volunteers. Moreover, the mutation was identified in 3 relatives of patient, who will 
then benefit from regular clinical cardiac follow-up and early treatment.  
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LMNA variant Mutation type Pathogenicity of mutation (+/-) 
R89L substitution: Arg to Leu + 
R101P substitution: Arg to Pro + 
R166P substitution: Arg to Pro + 
R190Q substitution: Arg to Gln + 
E203K substitution: Glu to Lys + 
I210S substitution: Ile to Ser + 
L215P substitution: Leu to Pro + 
A318T substitution: Ala to Thr - 
R388H substitution: Arg to His + 
R399C substitution: Arg to Cys - 
S437Hfsx1 
substitution: Ser to His, frameshift, 
STOP codon (nonsense) 
+ 
R471H substitution: Arg to His - 
R654X STOP codon (nonsense) + 
Table 2. LMNA variants inspected in patients with DCM (Cowan et al., 2010). 
2.2 Cardiac troponin T (TNNT2) 
Troponin T is the tropomyosin-binding protein in the troponin regulatory complex located 
on the thin filament of the contractile apparatus (see Figure 2). There are three isotype forms 
of troponin T: fast skeletal muscle, slow skeletal muscle and cardiac troponin T. These 
muscle-specific isoforms are expressed by different genes. Further diversity of troponin T 
comes from alternative splicing of RNA molecule (Katus et al., 1992). 
 
 
Fig. 2. Location of troponin T in the troponin regulatory complex. 
Cardiac troponin T is encoded by TNNT2 gene, which alterations significantly contribute 
to dilated cardiomyopathy. Kamisago et al. (2000) were one of the first to show the role 
of TNNT2, identifying a deletion of AGA triplet resulting in deletion of lysine in residue 
210 (K210 deletion) of troponin T protein chain in samples from two unrelated families 
suffering DCM. K210 mutation is one of the most frequent variants observed in patients 
suffering DCM. Otten et al. (2010) carried out a study, identifying 6 DCM patients 
carrying K210 deletion from 4 Dutch families. These patients showed severe form of 
DCM with early disease manifestation (mean age of DCM manifestation was 33 years). 
Moreover, heart transplantation was required in three patients at ages 12, 18 and 19 
years. 
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The evidence from large cohort of patients was further provided by Mogensen et al. (2004). 
The researchers performed the study on 235 patients suffering DCM (102 with FDC). 
Mutation analysis of TNNT2 resulted in identification of three novel mutations (R131W, 
R205L and D270N) and one reported previously(K210 deletion) in 13 patients from 4 
families. Three out of 13 patients received cardiac transplants, three died of heart failure, 
another three died suddenly and four remained stable on conventional heart failure therapy. 
All mutations segregated with the disease in each family and were absent in the control 
group and in the group of patients with hypertrophic cardiomyopathy (HCM). Identified 
mutations were considered disease-causing, because they co-segregated with disease in each 
family, were absent in control and HCM groups and were localized in conserved and 
functionally important regions of gene. Moreover, functional studies of mutated protein 
revealed altered troponin protein-protein interactions. 
Additional data concerning the role of TNNT2 mutations in DCM was delivered by 
Hershberger et al. (2009b). The researchers carried out bidirectional sequencing of TNNT2 
using DNA samples from 313 unrelated probands with DCM (183 with FDC and 130 with 
IDC). Six protein-altering mutations were identified in 9 probands (2.9% of all patients). 
None of these variants were present in control group (253 patients). Five variants were 
missense mutations altering highly conserved amino acids (four novel mutations: R134G, 
R151C, R159Q, R205W and one previously reported in HCM:E244D)and one was K210 
deletion. All of these mutations were considered possibly or likely disease-causing based on 
the clinical, pedigree and molecular genetic data (see Table 3). Additional functional studies 
of these mutations, carried out in cardiac myocytes reconstituted with mutant troponin T 
proteins revealed decreased Ca2+ sensitivity of force development (a hallmark of DCM), 
supporting disease-causing potential of these genetic variants. 
 
TNNT2 variant Mutation type Disease-causing 
R134G substitution: Arg to Gly 
yes (segregated with disease in other 
affected family members) 
R151C substitution: Arg to Cys 
yes (homozygous mutation associated 
with aggresive disease) 
R159Q substitution: Arg to Gln yes (replacement of conserved amino acid) 
R205W substitution: Arg to Trp 
yes (similar to disease-causing R205L 
mutation reported by Mogensen et al., 
2004) 
E244D substitution: Glu to Asp 
yes (reported as disease-causing in patient 
with HCM) 
K210del deletion of lysine 
yes (reported as disease-causing in several 
cases) 
Table 3. Disease-causing TNNT2 variants observed in patients with DCM (Hershberger et 
al., 2009b)  
Mutations in TNNT2 may be also associated with more than one type of cardiomyopathy. 
For example, Menon et al. (2008) study conducted on a family with autosomal dominant 
heart disease variably expressed as restrictive cardiomyopathy (RCM), HCM and DCM 
revealed cosegregation of TNNT2 mutation with disease phenotype. Sequencing of TNNT2 
identified a heterozygous missense mutation resulting in I79N substitution inherited by all 9 
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affected family members but none of the six unaffected relatives. Mutation carriers were 
diagnosed with RCM (2 patients), HCM (3 patients), DCM (2 patients), mixed 
cardiomyopathy (1 patient) and mild concentric left ventricular hypertrophy (1 patient). 
An experiment on mice, carried out by Ahmad et al. (2008) revealed the role of cardiac 
troponin T quantity and function in development of heart and in dilated cardiomyopathy. 
The researchers created heterozygous TNNT2+/- mice (i.e. lacking one TNNT2 allele) and 
then crossbred them to obtain homozygous null TNNT2-/- embryos. Moreover, transgenic 
mice overexpressing wildtype (TGWT) or mutant (TGK210Δ: K210 deletion) TNNT2 were also 
generated and used to create individuals lacking one allele of TNNT2 and carrying wildtype 
(TNNT2+/-/ TGWT) or mutant (TNNT2+/-/ TGK210Δ) transgenes. The scientists found out that 
TNNT2+/- mice compared to wildtype had significantly reduced transcript but not protein. 
Moreover, TNNT2+/- mice had normal hearts. On the other hand TNNT2+/-/ TGK210Δ mice 
had severe DCM whileTGK210Δ only mild DCM, suggesting the role of greater ratio of 
mutant to wildtype TNNT2 transcript in TNNT2+/-/ TGK210Δ mice compared to TGK210Δ 
individuals. TNNT2+/-/ TGK210Δ also showed muscle Ca2+ desenization but no difference in 
maximum force generation. The TNNT2-/- embryos had normally looped hearts but thin 
ventricular walls, large pericardial effusions, noncontractile hearts and severely 
disorganized sarcomers.  
2.3 β-myosin heavy chain (MYH7) 
Myosin is a protein that converts chemical energy into mechanical force through hydrolysis 
of ATP. Within the cell, it is organized as a pair of heavy chains and two pairs of light 
chains. The myosin heavy chain is a highly asymmetric molecule with a predominantly 
globular head and a rod-like tail, which is formed of two ǂ-helices and accounts for the 
formation of the thick filament backbone (see Figure 3). The globular head contains a light-
chain-binding domain and a catalytic domain with actin and ATP-binding sites (Kabaeva 
2002). 
 
 
Fig. 3. A pair of myosin heavy chains. 
Currently, more than 70 different mutations have been identified in MYH7 gene in association 
with DCM (Tanjore et al., 2010). Moreover, mutations in MYH7 have been reported in 4.2% 
cases of dilated cardiomyopathy (Hershberger et al., 2008). Clinical evaluations carried out in 
21 kindreds with FDC delivered first data suggesting the role of MYH7 mutations in dilated 
cardiomyopathy (Kamisago et al., 2000). A genome-wide linkage study revealed genetic locus 
for mutations associated with DCM located at chromosome 14q11.2-13, encoding the gene for 
Head 
Head 
Tail 
Tail 
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cardiac ǃ-myosin heavy chain. Disease-causing dominant mutations of MYH7 (S532P and 
F764L) were identified in 4 kindreds, resulting in early-onset ventricular dilatation (average 
age: 24 years) and diminished contractile function. 
Two novel mutations were identified in the study conducted by Kärkkäinen et al. (2004), 
carried out on 52 DCM Finnish patients. Screening of MYH7 coding regions resulted in 
identification of R1053Q and R1500W mutations in two patients. The R1500W mutation was 
associated with typical DCM phenotype. On the other hand, patient with R1053Q variant 
had dilated left ventricle and impaired systolic function, but other family members carrying 
this mutation had septal hypertrophy, suggesting that this variant was primarily an HCM 
mutation which could also lead to DCM. 
Additional MYH7 mutations were identified by Villard et al. (2005). The researchers 
screened all coding regions of MYH7 and TNNT2 gene in 96 independent patients (54 with 
FDC and 42 with IDC), identifying seven new mutations in MYH7 gene (see Table 4). 
Moreover, contrasting clinical features were observed between MYH7 and TNNT2 mutation 
carriers: mean age at diagnosis was late, penetrance was incomplete in adults and mean age 
at major cardiac event was higher in MYH7 mutation carriers compared to TNNT2. 
 
MYH7 variant Mutation type 
Affected part of myosine heavy 
chain 
I201T substitution: Ile to Thr head 
T412N substitution: Thr to Asn head 
A550V substitution: Ala to Val head 
T1019N substitution: Thr to Asn tail 
R1193S substitution: Arg to Ser tail 
E1426K substitution: Glu to Lys tail 
R1634S substitution: Arg to Ser tail 
Table 4. Disease-causing MYH7 variants observed in patients with DCM (Villard et al., 2005) 
Hershberger et al. (2008) in a study carried out on a cohort of 313 patients identified 12 
mutations in MYH7 gene (9 novel): R237W, V964L, A970V, R1045C, D1096Y, R1359C, 
R1500W, E1619K, V1692M, G1808A, H1901Q and R1863Q. These variants were observed in 
13 out of 313 probands (4.2%), revealing that MYH7 was the most commonly mutated gene 
in studied group. All observed variants were considered possibly or likely disease-causing. 
Additional two mutations were described by Boda et al. (2009) in the group of 100 DCM 
patients. Screening of MYH7 gene revealed a substitution G377R in one DCM patient, 
diagnosed at the age of 11 years and R787H substitution in another patient, diagnosed at the 
age of 7 years. Møller et al. (2009) identified three MYH7 mutations (K637E, resulting in 
charge change in actin cleft, L1038P introducing helix-breaking proline in the rod and 
R1832C resulting in loss of plus charge in light meromyosin and introduction of reactive 
cysteine) in one-quarter of studied DCM patients. 
Tanjore et al. (2010) in the study carried out on 292 individuals (100 healthy controls, 95 
HCM and 92 DCM) revealed common genetic variation (5 SNPs) in exons 7, 12, 19 and 20 of 
MYH7 gene for DCM and HCM patients. However, three out of 5 variants were 
heterozygous in HCM, whereas the same SNPs were found to be homozygous in DCM 
patients, revealing the dose effect of the protein with the gross anatomical variations in the 
ventricles leading to heart failure in DCM cases. 
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Rare mutations explain only a small percentage of DCM cases. Rampersaud et al. (2009) 
assumed that more common variants may also play a role in increasing susceptibility to 
DCM, similarly to observations in other common complex diseases. To verify that 
hypothesis, case-control analyses were performed on all DNA polymorphic variation 
identified in a resequencing study of six genes associated with DCM carried out on 477 
individuals (289 probands with DCM and 188 controls). Multivariate analyses revealed that 
a block of 9 MYH7 variants was strongly associated with DCM. 
3. Other genes involved in development of DCM 
Variation in three genes discussed above is considered to explain abut 10% of DCM cases. 
There are however other genetic factors that can also play role in development of dilated 
cardiomyopathy. 
SCN5A gene encodes alpha subunit of type V voltage-gated sodium channel (see Figure 4), 
which is abundant in cardiac muscle and controls the flow of sodium ions into cardiac muscle 
cells, playing major role in signalling start of each heartbeat, coordinating the contractions of 
the upper and lower chambers of heart and maintaining normal heart rhythm. 
 
 
Fig. 4. Structure of the C-terminal Ef-hand domain of human cardiac sodium channel. 
Available from http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=68594 
(Chagot et al., 2009). 
Mutations in SCN5A has been described as causative in long QT syndrome and dilated 
cardiomyopathy. McNair et al. (2004) carried out a research on a large family affected by an 
autosomal cardiac conduction disorder associated with sinus node dysfunction, arrhythmia 
and ventricular dilatation and dysfunction. Linkage analyses mapped the disease phenotype 
to a region on chromosome 3p22-p25, containing cardiac sodium channel gene SCN5A. 
SCN5A gene was screened in 21 subjects, revealing a heterozygous G to A substitution at 
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position 3823, changing aspartic acid to asparagine (D1275N) in highly conserved residue. 
The mutation was present in all affected family members (19 patients), while being absent in 
300 control chromosomes, and predicted a change of charge within the S3 segment of 
protein domain III. All of mutations changed conserved amino acids. Two novel variants 
segregated with FDC in families and were considered likely disease-causing. On the other 
hand, two variants associated also with Brugada syndrome (R526H) and long QT-syndrome 
(A572D) did not segregate with DCM. 
 
SCN5A 
variant 
Mutation type 
Pathogenicity of 
mutation (+/-) 
Also associated with 
S216L substitution: Ser to Leu + LQT syndrome 
R222Q substitution: Arg to Gln + - 
R526H substitution: Arg to His - Brugada syndrome 
A572D substitution: Ala to Asp - LQT syndrome 
P648L substitution: Pro to Leu + LQT syndrome 
I1835T substitution: Ile to Thr + - 
P2005A substitution: Pro to Ala + LQT syndrome 
Table 5. SCN5A variants observed in patients with DCM (Hershberger et al., 2008) 
A study performed on 338 DCM patients from Familial Cardiomyopathy Registry 
revealed 5 missense SCN5A mutations, including novel E446K, F1520L, V1279I and 
already described D1275 and R222Q. Mutations were detected in 1.7% of DCM families. 
Most of them were localized to the highly conserved homologous S3 and S4 
transmembrane segments , suggesting a shared mechanism of disruption of the voltage-
sensing mechanism of this channel leading to DCM. Patients carrying SCN5A mutations 
showed strong arrhythmic pattern that had clinical and diagnostic implications (McNair 
et al., 2011). 
Titin-cap (or telethonin), encoded by TCAP gene, is a protein regulating sarcomere 
assembly. It has kinase activity and serves as attachment for myofibrils and other muscle-
related proteins (Valle et al., 1997). Mutations in TCAP gene were described in association 
with cardiomyopathies. Hayashi et al. (2004) analyzed TCAP genotype in 346 patients 
with HCM and 136 with DCM (34 FDC, 102 IDC), revealing two mutations in patients 
with HCM and one (E132Q substitution) in patient with DCM. Moreover, the researchers 
demonstrated that HCM-associated mutations augmented the ability of titin-cap to 
interact with titin and calsarcin-1, whereas DCM-associated mutations impaired the 
interaction of titin-cap with muscle LIM protein, titin and calsarcin-1. The role of TCAP in 
development of DCM was also confirmed by Hershberger et al. (2008), who found three 
protein-altering variants of TCAP in 3 out of 313 DCM patients (with two variants 
segregating with disease). 
LDB3 (LIM domain binding 3), also known as ZASP or CYPHER is another gene associated 
with DCM. It encodes a protein containing PDZ domain which interacts with ǂ-actinin-2 
through its N-terminal PDZ domain and with protein kinase C through C-terminal LIM 
domains (a cysteine-rich motif containing two zinc-binding modules). It also interacts with 
myozenin family members. 
First data revealing the role of LDB3 in DCM was delivered by Vatta et al. (2003). The 
research was carried out on 100 DCM probands and resulted in identification of 5 mutations 
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(substitutions: S196L, I352M, D117N, K136M and T213I) in 6 patients (two families and four 
sporadic cases). None of these mutations were identified in the control group (200 
individuals). 5 out of 6 mutations resulted in substitutions in conserved regions and all lied 
within the linker between PDZ and LIM domains. In vitro studies showed cytoskeleton 
disarray in cells transfected with mutated LDB3. One additional mutation in LDB3 was 
discovered by Arimura et al. (2004) in the study carried out on 96 unrelated Japanese 
patients with DCM. D626N substitution located within the LIM domain was identified in a 
familial case but not in the unrelated controls. A family study showed that all affected 
siblings had the same mutation, associated with late onset cardiomyopathy. A yeast two-
hybrid assay demonstrated that described mutation increased the affinity of LIM domain for 
protein kinase C, suggesting a novel biochemical mechanism of the pathogenesis of DCM. 
Hershberger et al. (2008) identified two mutations in the LIM domain of LDB3 (A371T and 
A698T). Second mutation was identified in two unrelated probands and was predicted to 
change highly conserved amino acid; therefore it was considered disease-associated. 
TPM1 is a gene encoding tropomyosin ǂ-1 protein and another candidate gene for DCM. 
Tropomyosines are highly conserved actin-binding proteins involved in the contractile 
system of striated and smooth muscles and cytoskeleton of non-muscle cells. TPM1 forms 
predominant tropomyosine of striated muscle and functions in association with troponin 
complex to regulate calcium-dependent interaction of actin and myosin during muscle 
contraction. Mutations in this gene are associated with HCM and also DCM. Lakdawala et 
al. (2010) performed direct sequencing of 6 sarcomere genes on 334 probands with DCM, 
revealing D230N missense mutation in TPM1 gene, which segregated with DCM in two 
large unrelated families. Additional in vitro studies demonstrated major inhibitory effects on 
sarcomere function with reduced Ca2+ sensitivity, maximum activation and Ca2+ affinity 
compared to wildtype TPM1. 
A role of presenilin genes in dilated cardiomyopathy was described by Li et al. (2006). 
Presenilins are multi-pass transmembrane proteins which function as a part of Ǆ-secretase 
intramembrane protease complex. There are two presenilin genes in human genome: PSEN1 
and PSEN2, both showing conservation between species. Mutations in these genes are the 
most common cause of Alzheimer’s disease. They are also expressed in the heart and play 
critical role in cardiac development. The researchers analyzed sequence variation of PSEN1 
and PSEN2 in 315 patients with DCM, revealing novel PSEN1 mutation D333G in one 
family and a single PSEN2 mutation S130L in two other families. Both mutations segregated 
with DCM and heart failure. PSEN1 mutation was associated with complete penetrance and 
progressive disease that resulted in the necessity of cardiac transplantation or in death, 
whereas carriers of PSEN2 mutation showed partial penetrance, milder disease and more 
favourable prognosis. Moreover, calcium signalling was altered in cultured fibroblasts from 
mutation carriers. 
Genes that are associated with complex diseases can also be organized as linkage 
disequilibrium clusters that are often inherited together. Friedriechs et al. (2009) described 
such 600-kb region of linkage disequilibrium on 5q31.2-3 chromosome, harboring multiple 
genes to be associated with DCM in three independent Caucasian populations. Functional 
assessments in zebrafish demonstrated that at least three genes from this region (HBEGF – 
heparin-binding epidermal growth factor, IK cytokine and SRA1 – steroid receptor RNA 
activator 1) resulted independently in a phenotype of myocardial contractile dysfunction 
under the condition of reduced expression. 
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Most of the genes associated with DCM phenotype are present in nuclear genome. There are 
however examples of mitochondrial genes that can also contribute to development of 
dilated cardiomyopathy. Ashrafian et al. (2010) described C452F mutation in highly 
conserved region of the M domain of Dnm1l (dynamin1-like gene) in mice, resulting in 
reduced levels of mitochondria enzyme complexes in hearts, which then suffered from ATP 
depletion (energy deficiency that might contribute to DCM). 
4. Conclusions 
It is always difficult to find genetic cause of multigenic disorders, such as dilated 
cardiomyopathy, especially if it is considered that mutations in genome are only one of 
factors contributing to disease. Nevertheless, knowledge about genetic basis underlying 
such diseases proves to be very useful both in diagnostics and treatment, providing the 
possibility of early diagnosis and thus increasing the chance of successful therapy. 
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